In pancreatic carcinoma EGFR overexpression is measured in ~30% of cases and cytoplasmic overexpression of EGFR is considered a marker of poor prognosis in the ductal adenocarcinoma subtype [220]. This evidence concerns the gene EGFR and invasive ductal breast carcinoma.